Centromeric KIR AA Individuals Harbor Particular KIR Alleles Conferring Beneficial NK Cell Features with Implications in Haplo-Identical Hematopoietic Stem Cell Transplantation
Léa Dubreuil(Centre National de la Recherche Scientifique), Christelle Retière(Centre National de la Recherche Scientifique), Patrice Chevallier(Hotel Dieu Hospital), Katia Gagne(Inserm), Agnès Quéméner(Centre National de la Recherche Scientifique), Nolwenn Legrand(Centre National de la Recherche Scientifique), Dhon Roméo Makanga(Centre National de la Recherche Scientifique), Marie C. Béné(Centre Hospitalier Universitaire de Nantes), Catherine Willem(Centre National de la Recherche Scientifique), Ketevan Gendzekhadze(City Of Hope National Medical Center), Gaëlle David(Centre National de la Recherche Scientifique), Bercelin Maniangou(Centre National de la Recherche Scientifique), Mehdi Alizadeh(Établissement Français du Sang), Anne Cesbron(Services déconcentrés d'appui à la recherche Pays de la Loire)
Cited by 20
Related Papers
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party
|Blood|2018|1k
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party
|Blood|2021|714
Pediatric-Inspired Therapy in Adults With Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia: The GRAALL-2003 Study
|Journal of Clinical Oncology|2009|562
Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia
|Blood|2013|358
Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2016|347